Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emerging Companies

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

- PMLiVE

AZ says cancer will be ‘sixth growth platform’

Firm currently has 14 drugs in phase III trials

EISAI

Eisai establishes neuroscience unit in Belgium and Luxembourg

Follows the company's recent expansion in Australia

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

- PMLiVE

Eisai’s cancer cookbook wins CSR award

Around the Kitchen Table project see success at PMEA 2014

EISAI

Eisai opens first office in Australia

New Melbourne base to support marketing of Halaven and Fycompa

EISAI

Eisai “speechless” as G-BA denies price premium for Fycompa

But company has better news on cancer drug Halaven

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

- PMLiVE

Eisai backs competition to find star of epilepsy comic book

Teams up with Medikidz to educate young people about the condition

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links